Getting 'real' with real-world data: Discussing benefits & challenges of RWD in clinical trials


Zoom  
Wednesday, September 28, 2022 11:30 AM - 1:00 PM   Add to Calendar Central Standard Time

Join executive leaders from Walgreens, AbbVie, Cardinal, and Foley Partners as they discuss how their organizations are using real-world evidence (RWE) to move the needle on clinical trials to improve access to medications. Today, clinical research, and the data collected within it, need to be more reflective of the real-world settings in which patients live, so that providers can better close care gaps and improve outcomes. As such, RWE is playing an increasing role in healthcare and regulatory decision making, especially as the US Food and Drug Administration (FDA) is more open to accepting RWE to support its assessment of medical products. However, RWE stakeholders lack a shared understanding of the FDA’s expectations for the use of RWE in applications and research for new drugs and biologics. As the healthcare and life sciences industry further develops common standards, structures and processes around RWE generation, consideration must be made to use cases that support the FDA's recent steps to increase racial and ethnic diversity in clinical trials.

HBA Chicago-Northern Suburbs presents

Getting 'real' with real-world data: Discussing benefits & challenges of RWD in clinical trials


Date and time
Wednesday, 28 September
11:30AM - 01:00PM CST
Location
Zoom

Event Contact
Falguni Shah
Competencies
3. Exhibits business and industry acumen

Join executive leaders from Walgreens, AbbVie, Cardinal, and Foley & Lardner Partners as they discuss how their organizations are using Real World Data (RWD) to move the needle on clinical trials to improve access to medications.

Today, clinical research, and the data collected within it, need to be more reflective of the real-world settings in which patients live, so that providers can better close care gaps and improve outcomes. As such RWD is playing an increasing role in healthcare and regulatory decision making, especially as the US Food and Drug Administration (FDA) is more open to accepting RWD to support its assessment of medical products. However, stakeholders lack a shared understanding of the FDA's expectations for the use of RWD in applications and research for new drugs and biologics.

As the healthcare and life sciences industry further develops common standards, structures and processes around RWD, consideration must be made to use cases that support the FDA's recent steps to increase racial and ethnic diversity in clinical trials.

Registration information
Event is open to: HBA Members and Nonmembers

Featured Speakers

Monica  Chmielewski
Attorney - Partner
Foley & Lardner, LLP
Kim  Ribeiro
Head, Diversity and Patient Inclusion
AbbVie Inc.
Ramita  Tandon
Chief Clinical Trials Officer
Walgreens Boots Alliance
Aklilu  Tedla
VP, GM, Insights & Engagement, Regulatory Sciences, Advanced Therapy Solutions
Cardinal Health

Registration information

The registration button at the bottom of the page will not show if online registration has closed or if the event has reached capacity. If you are a guest and the registration button is not showing, it may be that this is a member-only event. Read more about the benefits of membership or contact us about membership.

The HBA will make reasonable modifications to policies and programs to ensure that people with special needs have an equal opportunity to enjoy all of its programs. Contact us if you require special accommodations for this event.

 Price LevelRegular
Collapse group

Registration: Regular Registration

 Member$10.00
 Member - Euro€8.00
 Non-Member$20.00
 Non-Member - Euro€17.00

By registering for this event, you acknowledge that you may be photographed, videotaped and/or audio-taped during the course of the meeting and hereby give permission for your image, voice, or survey comments to be used in education, training, promotion and/or trade and communications media by the Healthcare Businesswomen's Association in any and all media throughout the world, without restriction as to frequency or duration of usage.